Brief: Guardant Health’S Infinityai Real-World Evidence Supports Approval Of Enhertu® For Previously Treated Patients With Her2-Positive Metastatic Solid Tumors In Japan
30/03/2026 15:11
March 30 (Reuters) - Guardant Health Inc GH.O: GUARDANT HEALTH’S INFINITYAI REAL-WORLD EVIDENCE SUPPORTS APPROVAL OF ENHERTU® FOR PREVIOUSLY TREATED PATIENTS WITH HER2-POSITIVE METASTATIC SOLID TUMORS IN JAPAN Source text: ID:nBw6RJ3tMa Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsU.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte